{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:37Z","timestamp":1707524437008},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,13]]},"DOI":"10.7759\/cureus.18742","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T13:53:21Z","timestamp":1634133201000},"source":"Crossref","is-referenced-by-count":1,"title":["A Comparison Between Cefepime and Piperacillin-Tazobactam in the Management of Septic Shock"],"prefix":"10.7759","author":[{"given":"Robert  C","family":"Ross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbie N","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth  K","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharyn  L","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J","family":"Franck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes A","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, et al.. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017, 43:304-377. 10.1007\/s00134-017-4683-6","journal-title":"Intensive Care Med"},{"key":"ref2","unstructured":"Centers for Disease Control and Prevention. Hospital toolkit for adult sepsis surveillance. (2018). Accessed: September 28, 2021: https:\/\/www.cdc.gov\/sepsis\/pdfs\/Sepsis-Surveillance-Toolkit-Aug-2018_508.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer M","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al.. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016, 315:801-810. 10.1001\/jama.2016.0287","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/0885066619828290","article-title":"The risk of acute kidney injury in critically ill patients receiving concomitant vancomycin with piperacillin-tazobactam or cefepime","volume":"35","author":"Molina KC","year":"2020","unstructured":"Molina KC, Barletta JF, Hall ST, Yazdani C, Huang V. The risk of acute kidney injury in critically ill patients receiving concomitant vancomycin with piperacillin-tazobactam or cefepime. J Intensive Care Med. 2020, 35:1434-1438. 10.1177\/0885066619828290","journal-title":"J Intensive Care Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1442","article-title":"Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam","volume":"34","author":"Burgess LD","year":"2014","unstructured":"Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014, 34:670-676. 10.1002\/phar.1442","journal-title":"Pharmacotherapy"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2018.08.007","article-title":"Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin\/tazobactam or cefepime in the intensive care unit","volume":"48","author":"Buckley MS","year":"2018","unstructured":"Buckley MS, Hartsock NC, Berry AJ, et al.. Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin\/tazobactam or cefepime in the intensive care unit. J Crit Care. 2018, 48:32-38. 10.1016\/j.jcrc.2018.08.007","journal-title":"J Crit Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy724","article-title":"Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal \u03b2-lactams with vancomycin","volume":"68","author":"Schreier DJ","year":"2019","unstructured":"Schreier DJ, Kashani KB, Sakhuja A, et al.. Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal \u03b2-lactams with vancomycin. Clin Infect Dis. 2019, 68:1456-1462. 10.1093\/cid\/ciy724","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1738","article-title":"Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study","volume":"36","author":"Hammond DA","year":"2016","unstructured":"Hammond DA, Smith MN, Painter JT, Meena NK, Lusardi K. Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study. Pharmacotherapy. 2016, 36:463-471. 10.1002\/phar.1738","journal-title":"Pharmacotherapy"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018757497","article-title":"Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin\/tazobactam: a prospective, multicenter study","volume":"52","author":"Mullins BP","year":"2018","unstructured":"Mullins BP, Kramer CJ, Bartel BJ, Catlin JS, Gilder RE. Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin\/tazobactam: a prospective, multicenter study. Ann Pharmacother. 2018, 52:639-644. 10.1177\/1060028018757497","journal-title":"Ann Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02658-18","article-title":"Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem","volume":"63","author":"Blevins AM","year":"2019","unstructured":"Blevins AM, Lashinsky JN, McCammon C, Kollef M, Micek S, Juang P. Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem. Antimicrob Agents Chemother. 2019, 63:e02658-18. 10.1128\/AAC.02658-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt477","article-title":"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis","volume":"69","author":"Slimings C","year":"2014","unstructured":"Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014, 69:881-891. 10.1093\/jac\/dkt477","journal-title":"J Antimicrob Chemother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2013.10.001","article-title":"The impact of cefepime as first line therapy for neutropenic fever on Clostridium difficile rates among hematology and oncology patients","volume":"24","author":"Muldoon EG","year":"2013","unstructured":"Muldoon EG, Epstein L, Logvinenko T, Murray S, Doron SI, Snydman DR. The impact of cefepime as first line therapy for neutropenic fever on Clostridium difficile rates among hematology and oncology patients. Anaerobe. 2013, 24:79-81. 10.1016\/j.anaerobe.2013.10.001","journal-title":"Anaerobe"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1514-2","article-title":"Do piperacillin\/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?","volume":"16","author":"Kundrapu S","year":"2016","unstructured":"Kundrapu S, Sunkesula VC, Jury LA, et al.. Do piperacillin\/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?. BMC Infect Dis. 2016, 16:159. 10.1186\/s12879-016-1514-2","journal-title":"BMC Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2015.01.002","article-title":"Sepsis-associated acute kidney injury","volume":"35","author":"Alobaidi R","year":"2015","unstructured":"Alobaidi R, Basu RK, Goldstein SL, Bagshaw SM. Sepsis-associated acute kidney injury. Semin Nephrol. 2015, 35:2-11. 10.1016\/j.semnephrol.2015.01.002","journal-title":"Semin Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta RL","year":"2007","unstructured":"Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007, 11:R31. 10.1186\/cc5713","journal-title":"Crit Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone EJ","year":"2017","unstructured":"Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017, 102:459-469. 10.1002\/cpt.726","journal-title":"Clin Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak MJ","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, et al.. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020, 77:835-864. 10.1093\/ajhp\/zxaa036","journal-title":"Am J Health Syst Pharm"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S308878","article-title":"Outcomes and nephrotoxicity associated with vancomycin treatment in patients 80 years and older","volume":"16","author":"Wang Y","year":"2021","unstructured":"Wang Y, Dai N, Wei W, Jiang C. Outcomes and nephrotoxicity associated with vancomycin treatment in patients 80 years and older. Clin Interv Aging. 2021, 16:1023-35. 10.2147\/CIA.S308878","journal-title":"Clin Interv Aging"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/73364-a-comparison-between-cefepime-and-piperacillin-tazobactam-in-the-management-of-septic-shock","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:35:16Z","timestamp":1707507316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/73364-a-comparison-between-cefepime-and-piperacillin-tazobactam-in-the-management-of-septic-shock"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.18742","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,13]]}}}